Chinese HIV carriers welcome the latest cutting-edge medicine for treatment by world’s noted drug producer GlaxoSmithKline (GSK), which offers a lower price making the new drug more accessible.

The new drug, Tivicay, entered the Chinese market on Tuesday, after receiving approval from the China Food and Drug Administration in January, the Southern Weekly reported.

In combination with other anti-retroviral medicines, Tivicay can be used for the treatment of HIV infected adults and children ages 12 and up.

“We are committed to working with the government to ensure that people living with HIV/AIDS have increased access to medicines … To achieve this we are ready to consider price-access type arrangements in the same spirit of the recent National Drug Price Negotiation pilot,” Herve Gisserot, senior vice president of GKS China/Hong Kong, was quoted as saying.

Under China’s policy for HIV treatment, people with economic problems can enjoy free treatment and the central and local governments will be responsible for purchasing the drugs under special government funds, international cooperation projects and other kinds of donations, according to Southern Weekly. It added that some patients spend over 10,000 yuan on HIV treatment drugs every month and the high cost of new drugs is usually a major obstacle for many patients.

China has over 570,000 HIV carriers as of October 2015, some 0.06 percent of the total population, the Southern Weekly noted, adding that the percentage of HIV carriers aged under 24 are worryingly on the rise over the past few years.